Abstract
Purpose
Reduced intensity therapy for children with low-risk febrile neutropenia may provide benefits to both patients and the health service. We have explored the safety of these regimens and the effect of timing of discharge.
Methods
Multiple electronic databases, conference abstracts and reference lists were searched. Randomised controlled trials (RCT) and prospective observational cohorts examining the location of therapy and/or the route of administration of antibiotics in people younger than 18 years who developed low-risk febrile neutropenia following treatment for cancer were included. Meta-analysis using a random effects model was conducted. I 2 assessed statistical heterogeneity not due to chance. Registration: PROSPERO (CRD42014005817).
Results
Thirty-seven studies involving 3205 episodes of febrile neutropenia were included; 13 RCTs and 24 prospective observational cohorts. Four safety events (two deaths, two intensive care admissions) occurred.
In the RCTs, the odds ratio for treatment failure (persistence, worsening or recurrence of fever/infecting organisms, antibiotic modification, new infections, re-admission, admission to critical care or death) with outpatient treatment was 0.98 (95% confidence interval (95%CI) 0.44–2.19, I 2 = 0 %) and with oral treatment was 1.05 (95%CI 0.74–1.48, I 2 = 0 %). The estimated risk of failure using outpatient therapy from all prospective data pooled was 11.2 % (95%CI 9.7–12.8 %, I 2 = 77.2 %) and using oral antibiotics was 10.5 % (95%CI 8.9–12.3 %, I 2 = 78.3 %). The risk of failure was higher when reduced intensity therapies were used immediately after assessment, with lower rates when these were introduced after 48 hours.
Conclusions
Reduced intensity therapy for specified groups is safe with low rates of treatment failure. Services should consider how these can be acceptably implemented.
Similar content being viewed by others
References
Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH (2005) Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 23(31):7958–7966
Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F et al (2007) A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 45(10):1296–1304
Ammann RA, Teuffel O, Agyeman P, Amport N, Leibundgut K (2015) The influence of different fever definitions on the rate of fever in neutropenia diagnosed in children with cancer. PLoS One 10(2), e0117528
Phillips RS, Lehrnbecher T, Alexander S, Sung L (2012) Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One 7(5), e38300
Teuffel O, Cheng S, Ethier MC, Diorio C, Martino J, Mayo C et al (2012) Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 20(11):2755–2764
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS (2013) Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group. Blood 121(18):3573–3577
Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR (1996) A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 128(6):847–849
Teuffel O, Amir E, Alibhai SMH, Beyene J, Sung L (2011) Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 127(2):e279–e286
Manji A, Beyene J, Dupuis LL, Phillips R, Lehrnbecher T, Sung L (2012) Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials. Support Care Cancer 20(6):1135–1145
Vidal L, Ben Dor I, Paul M, Eliakim-Raz N, Pokroy E, Soares-Weiser K et al (2013) Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 10, CD003992
Feld R, Paesmans M, Freifeld AG, Klastersky J, Pizzo PA, Rolston KVI et al (2002) Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the immunocompromised host society/multinational association for supportive care in cancer, with emphasis on outpatient studies. Clin Infect Dis 35(12):1463–1468
Morgan JE, Stewart L, Phillips RS (2014) Protocol for a systematic review of reductions in therapy for children with low-risk febrile neutropenia. Syst Rev 3(1):119
Higgins JPT, Green S, editors (2011) Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Verrsion 5.1.0. The Cochrane Collaboration. Available from: www.cochrane-handbook.org
National Institute for Health and Clinical Excellence. Appendix I: Methodology checklist: prognostic studies. From The guidelines manual [Internet]. London: National Institute for Health and Clinical Excellence; 2012 [cited 2014 Feb 14]. Available from: www.nice.org.uk/article/pmg6b/chapter/Appendix-I-Methodology-checklist-prognostic-studies
Brack E, Bodmer N, Simon A, Leibundgut K, Kuhne T, Niggli FK et al (2012) First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer 59(3):423–430
Cagol AR, Castro Junior CG, Martins MC, Machado AL, Ribeiro RC, Gregianin LJ et al (2009) Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J) 85(6):531–535
Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S (2009) Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 31(9):635–641
Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW et al (1999) Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86(1):126–134
Orme L, Babl F, Barnes C, Barnett P, Donath S, Ashley D (2014) Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. Pediatr Blood Cancer 61:1427–1433
Paganini H, Gomez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L et al (2003) Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina. Cancer 97(7):1775–1780
Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L et al (2001) Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 91(8):1563–1567
Paganini HR, Sarkis CM, De Martino MG, Zubizarreta PA, Casimir L, Fernandez C et al (2000) Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 88(12):2848–2852
Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A (2000) Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med Pediatr Oncol 34(2):87–91
Santolaya ME, Alvarez AM, Aviles CL, Becker A, Cofre J, Cumsille MA et al (2004) Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 22(18):3784–3789
Shenep JL, Flynn PM, Baker DK, Hetherington SV, Hudson MM, Hughes WT et al (2001) Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin Infect Dis 32(1):36–43
Varan A, Koksal Y, Akyuz C, Ceyhan M, Kanra G, Buyukpamukcu M (2005) The outpatient management of febrile neutropenia in selected children with cancer: a preliminary report. Pediatr Blood Cancer 45(4):512
Klaassen RJ, Allen U, Doyle JJ (2000) Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J Pediatr Hematol Oncol 22(5):405–411
Abbas AAH, Felimban SK, Cittana BA, Yousef AA, Fayea NY, Khattab TM et al (2003) Once daily ceftriaxone and amikacin for outpatient treatment of neutropenic fever in children with acute lymphoblastic leukaemia. Haema 6(4):501–506
Aquino VM, Herrera L, Sandler ES, Buchanan GR (2000) Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 88(7):1710–1714
Bash RO, Katz JA, Cash JV, Buchanan GR (1994) Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 74(1):189–196
Dommett R, Geary J, Freeman S, Hartley J, Sharland M, Davidson A et al (2009) Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. Eur J Cancer 45(16):2843–2849
Doyle JJ, King SM, Comay SA, Freedman MH (1996) Oral antibiotic therapy for “low risk” febrile neutropenic episodes (fne). Pediatr Res 39(S4):154
Fernandez CM, Saavedra-Lozano J, Huerta J, Garrido C, Belendez C, Cela E et al (2012) Risk-based therapy for febrile patients with neutropenia: a role for early hospital discharge. Pediatr Blood Cancer 59(6):1113–1114
Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R (1994) Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 30(8):649–651
Karthaus M, Egerer G, Jurgens H (2000) Outpatient treatment of cancer patients with fever and neutropenia. Antibiot Chemother 50:47–58
Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11(4):417–421
Malik IA (1997) Out-patient management of febrile neutropenia in indigent paediatric patients. Ann Acad Med Singapore 26(6):742–746
Miedema K, Tissing W, Van Vliet M, De Vries W, Kamps W, Abbink F et al (2012) Risk-adapted approach for fever and neutropenia in pediatric cancer patients. Support Care Cancer 20:S155
Paganini HR, Rodriguez Brieshcke T, Zubizarreta P, Latella A, Firpo V, Fernandez C et al (2001) Criteria of low risk of mortality in children with neutropenia and fever during cancer chemotherapy. Medicina (Mex) 61(1):63–66
Paganini H (2003) Tratamiento ambulatorio secuencia parenteral-oral de niños con neutropenia y fiebre de riesgo de mortalidad Sequential oral-parenteral outpatient treatment on low-risk children with fever and neutropenia. Arch Argent Pediatr 101(1):31–36
Paganini H (2000) Tratamiento secuencial parenteral-oral con antibióticos en niños con patología onco-hematológica con bajo riesgo de bacteriemia Sequential antibiotic parenteral-oral therapy in onco-hematologic patients with low-risk for bacteriemia. Arch Argent Pediatr 98(5):291–295
Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T (2003) Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol 40(2):93–98
Petrilli AS, Carlesse FA, Pereira CAP (2007) Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. Pediatr Blood Cancer 49(5):682–686
Phillips R, Phelan L, Picton S (2006) An audit of the use of oral antibiotics and early discharge in the treatment of low risk febrile neutropenia in children. Arch Dis Child 91(Suppl 1):A80–A82
Preis S, Jurgens H, Friedland C, Oudekotte-David AA, Thomas L, Gobel U (1993) Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Padiatr 205(4):295–299
Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA (2007) Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatr Blood Cancer 48(3):273–277
Sari N, Aki A, Ocal R, Karaman N, Ilhan I (2007) Oral ciprofloxacin and amoxicillin/clavulanate treatment in pediatric cancer patients with low-risk febrile neutropenia. Pediatr Blood Cancer. 481
Shrestha PN, Sah KP, Rana R (2009) Emperical oral antibiotic therapy for children with low risk febrile neutropenia during cancer chemotherapy. J Nepal Paediatr Soc 29(1):22–25
Tordecilla CJ, Campbell Bull M, Joannon SP, Rizzardini LC, Soto AV (1998) Criterios de alta precoz en niños con cáncer y neutropenia febril criteria of early discharge in children with cancer and febrile neutropenia. Rev Chil Pediatr 69(6):247–251
Wiernikowski JT, Rothney M, Dawson S, Andrew M (1991) Evaluation of a home intravenous antibiotic program in pediatric oncology. Am J Pediatr Hematol Oncol 13(2):144–147
Ablett S, Pinkerton CR (2003) Recruiting children into cancer trials—role of the United Kingdom Children’s Cancer Study Group (UKCCSG). Br J Cancer 88(11):1661–1665
Acknowledgments
We would like to acknowledge Kate Lewis-Light for her work on the searching for this review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
JM is funded by Candlelighters Children’s Charity (Registered Charity No: 1045077) for the PhD of which this systematic review is a part.
Conflict of interest
The authors declare that they have no competing interests.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Online Resource 1
Database search strategies (PDF 194 kb)
Online Resource 2
Reasons for study exclusions (PDF 317 kb)
Online Resource 3
Demographics of included studies (PDF 500 kb)
Online Resource 4
Study interventions and definitions (PDF 451 kb)
Rights and permissions
About this article
Cite this article
Morgan, J.E., Cleminson, J., Atkin, K. et al. Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer 24, 2651–2660 (2016). https://doi.org/10.1007/s00520-016-3074-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-016-3074-9